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ABSTRACT
With the aim to discover new STAT3 direct inhibitors, potentially useful as anticancer agents, a set of
methanethiosulfonate drug hybrids were synthesized. The in vitro tests showed that all the thiosulfonic
compounds were able to strongly and selectively bind STAT3-SH2 domain, whereas the parent drugs were
completely devoid of this ability. In addition, some of them showed a moderate antiproliferative activity
on HCT-116 cancer cell line. These results suggest that methanethiosulfonate moiety can be considered a
useful scaffold in the preparation of new direct STAT3 inhibitors. Interestingly, an unusual kind of organo-
sulfur derivative, endowed with valuable antiproliferative activity, was occasionally isolated.
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Signal transducer and activator of transcription 3 (STAT3) were
identified in 1994 as a DNA-binding factor that selectively interacts
with IL-6-responsive element in the promoter of acute-phase
genes from IL-6-stimulated hepatocytes1. It belongs to STAT fam-
ily, latent cytoplasmic transcription factors that are activated in
response to extracellular signals such as cytokines, growth factors,
and hormones. STATs directly transmit signals from plasma mem-
brane to the nucleus and regulate cell growth and survival by
modulating the expression of specific target genes. This family
comprises seven isoforms, namely STAT1 to STAT4, STAT5a,
STAT5b, and STAT62, that present several structurally and function-
ally conserved domains including the Src homology 2 (SH2)
domain which is essential for the activation cascade pathway.
Upon phosphorylation in the cytoplasm, STAT3 can dimerize form-
ing homodimers or heterodimers through specific reciprocal
SH2-phosphotyrosine interaction; the dimers then translocate into
the nucleus, bind to specific DNA-binding elements, and activate
transcription of target genes, which are mainly involved in cell
proliferation, differentiation, apoptosis, and inflammation3.
In addition, STAT3 was found to be constitutively activated by
aberrant upstream tyrosine kinase activity in a broad spectrum of
cancer cell lines and human tumors, and therefore it is considered
a promising target for cancer therapy. Several studies confirmed
that STAT3 inhibitors have minimal effects on normal cells4,5, thus
providing the potential for selective tumor cell elimination.
Two main approaches have been explored to inhibit STAT3 sig-
naling6,7: direct, by interaction of small molecules with the protein
and indirect, inhibiting the upstream tyrosine kinases that are
responsible for STAT3 activation or blocking factors as JAK, Src,
Bcr-Abl, FLT3, and EGFR that are involved in the activation of
STAT3 signaling. This kind of inhibition induces tumor-cell apop-
tosis but it is poor selective.
Direct inhibitors should be preferred because the nonspecific
mechanism of action of indirect inhibitors could cause important
adverse effects. In the direct approach, much of the efforts have
been addressed at disrupting the STAT3:STAT3 dimerization, which
is a fundamental step in STAT3 activation. The slow progress of
obtaining suitable direct STAT3 inhibitors for preclinical investiga-
tion and for clinical development could be attributed to the chal-
lenge of targeting protein-protein interactions (PPIs)8, which are
very different from those of more-established targets such as
enzymes and G-protein-coupled receptors. Nonetheless, a number
of successful examples started to prove that it is possible to over-
come these hurdles and develop PPI modulators as drugs9.
Recently, a number of small molecule compounds which dir-
ectly inhibit the activity and function of STAT3 have been discov-
ered and studied for cancer treatment and prevention10,11.
Among them, S3I-201 (Figure 1) has been identified as a
selective STAT3-SH2 domain inhibitor, which blocked the forma-
tion of STAT3 homodimers (IC50¼86 lM) and inhibited the prolif-
eration of breast and hepatocellular cancer cells in mice12.
However, the presence of an electrophilic tosylate leaving group
in S3I-201 renders it highly susceptible to alkylate also other sub-
strates, and therefore it is not very stable in the biological
medium. Further studies lead to the synthesis of several analogs
of S3I-201, able to bind the SH2 domain with higher affinity13–15.
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It is well known from literature that S-methyl methanethiosulfo-
nate (SMMTS), isolated from cauliflower, is able to inhibit colon
tumor incidence when administered to rats during the post-initi-
ation phase of carcinogenesis16.
Recently, we have synthesized and studied two methanethio-
sulfonate (MTS) derivatives (1 and 2; Figure 2)17 of valproic acid
(VA) endowed with interesting anticancer properties. In particular,
compound 1 exhibited in vitro antiproliferative activity at micro-
molar concentration on different tumor cell lines18,19 and in vivo
inhibited the growth of PC3 in subcutaneous xenografts18.
Although SMMTS16 and other MTS derivatives18,19 exert their
chemopreventive and anticancer activity through multiple mech-
anism, their hypothetical direct or indirect activity on STAT3 had
not been investigated yet. For this reason, to evaluate their ability
to interact with STAT3-SH2 domain, we submitted compounds 1
and 2 to the AlphaScreen-based assay20, an in vitro competitive
binding test used to identify compounds able to directly inhibit
the binding of SH2-containing proteins to their correspondent
phosphopeptides, the physiological ligands.
Since both compounds showed a potent inhibition of the bind-
ing between STAT3-SH2 domain and its phosphopeptidic ligand,
we decided to extend this investigation to other thiosulfonate-
drug hybrids (Figure 2), as well as to their parent compounds,
with the aim to better understand and confirm the behavior of
the thiosulfonate moiety toward this protein.
NSAIDs-thiosulfonate hybrids 3, 4, and 5, which are derivatives
of sulindac, acetyl salicylic acid (ASA), and diclofenac, respectively,
have been chosen because it is known that COX inhibitors are use-
ful in the treatment of certain kind of tumors. The idea was that the
combination of COX inhibition with the anticancer properties of
thiosulfonates could lead to a new chemical entity where the two
components act in a synergistic way against cancer development.
The anticancer activity of NSAIDs seems also related to add-
itional mechanisms. Indeed, ASA induced apoptosis in colorectal
cancer (CRC) cells in aspirin-treated mice21 or in human glioblast-
oma cell line A172 via downregulation of IL-6-dependent STAT3
signaling22 suggesting that aspirin could be useful for a potential
anti-glioblastoma or anti-CRC therapeutic approach. Also sulindac
treatment exerted a significant time-dependent cell growth-inhibi-
tory effect on oral squamous cell carcinoma (SCCa) cells inducing
a STAT3 down-modulation23. Since the above-mentioned activities
seem to be related to the downregulation of STAT3 pathway and
not to a direct interaction with the STAT3-SH2 domain, we
thought that the linkage of a NSAID drug with a direct STAT3
inhibitor, such as a thiosulfonate derivative, could be a useful
strategy to obtain a more powerful STAT3 inhibitor.
In addition, we decided to modify the structure of compound
S3I-201 through the replacement of the oxygen with a sulfur atom,
thus obtaining compound 6 (Figure 1) or through the replacement
of the tosylate group with the methanethiosulfonate (compound 7,
Figure 1). The aim was to evaluate if the presence of the thiosulfo-
nate moiety can modify both the ability of S3I-201 to interact with
STAT3 and its potency as antiproliferative agent. Actually, com-
pound 7 was not obtained, and compound 8 was instead isolated.
Materials and methods
General
All commercially available solvents and reagents were used with-
out further purification, unless otherwise stated. Reactions moni-
tored by thin-layer chromatography (TLC) analysis on aluminum-
backed Silica Gel 60 plates (70–230 mesh, Merck). CC¼ flash
column chromatography (GeduranVR Si 60, 40–63 lm, Merck). 1H-
NMR and 13C NMR spectra: Bruker DRX Avance 300MHz or Varian
300MHz Oxford equipped with a non-reverse probe at 25 C;
CDCl3, DMSO-d6, D2O; d in ppm, J in Hertz. High-resolution mass
spectra (HRMS): FT-Orbitrap mass spectrometer in positive/Figure 1. Structure of S3I-201.
Figure 2. Structures of the studied thiosulfonate drug hybrids and of compound 8.
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negative electro spray ionization (ESI). Melting points: B€uchi
Melting Point B540 instrument, uncorrected.
Synthesis of hybrid compounds (1), (2) and (5)
2-((Methylsulfonyl)thio)ethyl 2-propylpentanoate (1), S-(2-(2-propyl-
pentanamido)ethyl) methanesulfonothioate (2) and 2-((methylsul-
fonyl)thio)ethyl 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate (5)
were prepared according to the literature procedures17,24.
(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-
indene-3-acetic acid 2-methanesulfonylsulfanylethyl ester (3)
and 2-acetoxybenzoic acid 2-methanesulfonylsulfanyl-ethyl
ester (4)
General method
A 1 N solution of dicyclohexylcarbodiimide (DCC, 4.22ml) in
CH2Cl2 was added to a solution of S-(2-hydroxyethyl) methanesul-
fonothioate25 (9; 3.84mmol), 4-dimethylaminopyridine (DMAP,
0.18mmol), and sulindac or acetyl salicylic acid (3.84mmol) in
CH2Cl2 (67ml), and the mixture was stirred for 1.5 h at room tem-
perature, under nitrogen. At the end of the reaction, the dicyclo-
hexylurea (DCU) was filtered and the solution was extracted
successively with a solution of 1 N HCl, afterward with water, then
with a saturated solution of NaHCO3 and water. Finally, the
organic phase was dried on anhydrous Na2SO4, filtered, and
evaporated to dryness. The residue was purified by CC on silica
gel as indicated for each compound.
The two compounds have been already described in two pat-
ents26,27, and their characterization is now integrated.
(Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-
indene-3-acetic acid 2-methanesulfonylsulfanylethyl ester (3)26
CC (CH2Cl2/MeOH, 99.5:0.5). Yield 80%; mp 118.5–119.5 C.
1H NMR
(300MHz, CDCl3): d 7.70 (dd, 4H, CH3SO2-Ar-H); 7.20 (s, 1H, F-Ar-H);
7.18 (d, 1H, F-Ar-H); 6.85 (d, 1H, F-Ar-H); 6.58 (t, 1H, C¼CH-); 4.40
(t, 2H, OCH2); 3.60 (s, 2H, Ar-CH2-COO); 3.40 (t, 2H, CH2-S); 3.30 (s,
3H, SO2-CH3); 2.80 (s, 3H, SO-CH3); 2.20 (s, 3H, -CH3).
2-Acetoxybenzoic acid 2-methanesulfonylsulfanyl-ethyl
ester (4)27
CC (cycloexhane/EtOAc, in gradient from 80:20 to 60:40). Yield 28%;
mp 90.5–91.3 C. 1H NMR (300MHz, CDCl3): d 8.00 (d, 1H, Ar-H); 7.60
(t, 1H, Ar-H); 7.30 (t, 1H, Ar-H); 7.10 (d, 1H, Ar-H); 4.60 (t, 2H, COO-
CH2); 3.50 (t, 2H, CH2-S); 3.40 (s, 3H, SO2-CH3); 2.40 (s, 3H, OCO-CH3).
2-((Methylsulfonyl)thio)acetic acid (15)
Sodium methanethiosulfonate (13; 500mg, 3.73mmol) and 2-bro-
moacetic acid (14; 470mg, 3.38mmol) were mixed together in
acetone (8ml). The reaction was stirred at room temperature for
20 h and was monitored by TLC. After the completion of reaction,
inorganic salts were filtered and the solution was evaporated
under reduced pressure. The resulting yellow pale oil was crystal-
lized with CH2Cl2 to provide the final product as a white crystal
solid. Yield 80%; mp 80.1–81.5 C (Lit. 95–96)28. 1H NMR (300MHz,
DMSO-d6): d 13.18 (br s, 1H, -COOH collapsed with D2O), 4.07 (s,
2H, -CO-CH2-S), 3.53 (s, 3H, -CH3) ppm.
2-Hydroxy-4-(2-(tosylthio)acetamido)benzoic acid (6)
Sodium toluenethiosulfonate29 (12; 812mg, 3.83mmol) and 4-(2-
chloroacetamido)-2-hydroxybenzoic acid30 (11; 805mg, 3.48mmol)
were dissolved in anhydrous DMF (7.5ml) under nitrogen. The
reaction was stirred at 60 C for 4 h and was monitored by TLC.
After cooling at room temperature, inorganic salts were filtered
and the solution was evaporated under reduced pressure. The
obtained residue was diluted with CH2Cl2 and washed with cold
water three times and then with iced brine. The organic layer was
dried with anhydrous Na2SO4, filtered and evaporated under
reduced pressure to dryness to provide a residue that was purified
by CC (silica gel; CH2Cl2/MeOH; in gradient), using the Flash
Chromatography Purification System Biotage SP-1; the product
eluted with 1.3% of MeOH. A salmon pink solid was obtained. The
solid was rinsed first with ethyl ether/petroleum ether (2:1) and
then with ethyl ether/MeOH (1:0.2) to give the final product as a
white solid. Yield 60%; mp 170.0–171.9 C. 1H NMR (300MHz,
DMSO-d6): d 11.41 (br s, 1H, -OH collapsed with D2O), 10.42 (s, 1H,
-NH- collapsed with D2O), 7.80 (d, 2H, J¼7.8 Hz, Ar-H), 7.71 (d,
1H, J¼ 8.8 Hz, Ar-H), 7.38 (d, 2H, J¼ 7.8 Hz, Ar-H), 7.11 (d, 1H,
J¼ 1.6 Hz, Ar-H), 6.91 (dd, 1H, J1¼1.6 Hz, J2¼8.8 Hz, Ar-H), 4.05 (s,
2H, -CH2-S-), 2.31 (s, 3H, Ar-CH3) ppm.
13C NMR (75MHz, DMSO-
d6): d 171.93, 165.09, 162.41, 145.56, 145.01, 141.48, 131.47, 130.47,
127.31, 110.67, 108.53, 106.59, 21.44 ppm. HRMS (ESI): m/z calcd
for C16H16NO6S2 [MþH]þ: 382.04190; found: 382.04130.
S-((methylsulfonyl)methyl) 4-amino-2-hydroxybenzothioate (8)
To a solution of 2-((methylsulfonyl)thio)acetic acid (15; 366mg,
2.15mmol) in anhydrous DMF (2ml) under argon and at 0 C,
hydroxybenzotriazole (HOBt, 290mg, 2.15mmol), N,N-diisopropyle-
thylamine (DIPEA, 0.341ml, 1.96mmol), and N-(3-dimethylamino-
propyl)-N0-ethylcarbodiimide hydrochloride (EDC-HCl, 412mg,
2.15mmol) were added. After 5-min p-aminosalicylic acid (300mg,
1.96mmol) was added, and the reaction was stirred at room tem-
perature for 6 h. The reaction was monitored by TLC. After the
completion of reaction, the solution was evaporated under
reduced pressure. The obtained residue was diluted with EtOAc
and washed first with a cold solution of 0.5 N HCl and then with
cold brine. The organic layer was dried with anhydrous Na2SO4, fil-
tered, and evaporated under reduced pressure to dryness, and the
crude product was then purified by CC (silica gel; CH2Cl2/MeOH; in
gradient); the product eluted with 0.3% of MeOH. After washing
with diethyl ether, a white solid was obtained. Yield 6%; mp
199.6–202.3 C. 1H NMR (300MHz, DMSO-d6): d 10.67 (br s, 1H, OH
collapsed with D2O), 7.51 (d, 1H, J¼ 8.7 Hz, Ar-H), 6.43 (br s, 2H,
NH2 collapsed with D2O), 6.17 (dd, 1H, J1¼2.1 Hz and J2¼8.7 Hz,
Ar-H), 6.01 (d, 1H, J¼ 2.1 Hz, Ar-H), 4.66 (s, 2H, S-CH2-SO2), 2.98 (s,
3H, SO2-CH3) ppm.
13C NMR (75MHz, DMSO-d6): d 184.69, 161.68,
157.19, 131.72, 109.25, 107.76, 98.72, 49.48, 39.86 ppm. HRMS (ESI):
m/z calcd for C9H11NO4S2Na [MþNa]þ: 284.0027; found: 284.0024;
calcd for C9H12NO4S2 [MþH]þ: 262.0208; found 262.02044; calcd
for C9H10NO4S2 [M-H
þ]: 260.0057; found 260.0051.
Single crystal X-ray analysis (8)
Crystals of compound 8 were obtained as colorless prisms from
water/methanol (1:1) solution at room temperature, respectively.
Intensity data were collected at room temperature on a Bruker
Apex II CCD diffractometer, using graphite-monochromatized Mo-
Ka radiation (k¼ 0.71073Å). Intensity data were corrected for
Lorentz-polarization effects and for absorption (SADABS)31. The
structures were solved by direct methods (SIR97)32 and completed
by iterative cycles of full-matrix least squares refinement on Fo
2
and DF synthesis using the SHELX-9733 program (WinGX suite)34.
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The positions of hydrogen atoms were introduced by a close
examination of a final difference Fourier.
These data can be obtained free of charge via www.ccdc.cam.
ac.uk/conts/retrieving.html (or from the Cambridge
Crystallographic Data Center, 12, Union Road, Cambridge CB21EZ,
UK; fax:þþ44 1223 336 033; or deposit@ccdc.cam.ac.uk). CCDC-
1495448 number contains the supplementary crystallographic data
for this paper.
Crystal data for (8)
C9H11NO4S2, Mr¼ 261.3 g/mol, Triclinic, Space group P-1,
a¼ 5.080(3) Å, b¼ 9.8552(6) Å, c¼ 11.4649(7) Å, a¼ 81.569(1),
b¼ 88.232(1), c¼ 77.41(1), V¼ 554.12(6) Å3, Z¼ 2, Dcalc¼ 1.566Mg/
m3, R¼ 0.033 (5853 reflections), wR2¼ 0.0864, T¼ 293(2)K,
GOF¼ 1.080. The reflections were collected in the range
1.8  h 25.02 employing a 0.55 0.22 0.02mm crystal.
AlphaScreen-based assay
STAT3 inhibitory activity of the described compounds was tested
by the AlphaScreen-based assay to evaluate the potential inhib-
ition of the interaction between STAT3-SH2 domain and pTyr-con-
taining peptides according to the previously reported procedure20.
For the most interesting compounds, selectivity tests versus STAT1
and Grb2 (Growth factor receptor-bound protein 2) were per-
formed. AlphaScreen is a bead-based nonradioactive assay system
for detecting biomolecular interactions in a microtiter plate format.
Binding of biological partners brings donor and acceptor beads
into close proximity and as result, a luminescent signal between
520 and 620 nm is produced. The AlphaScreen-based assays were
typically performed in a final reaction volume of 25 ll of the assay
buffer containing 10mM HEPES–NaOH (pH 7.4), 50mM NaCl, 1mM
EDTA (pH 8.0), 0.1% NP-40, and 10 ng/ll BSA in a 96-well micro-
titer plate at 25 C. Phospho-Tyr (pTyr) peptide probes used in this
study were 5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3, FITC-
GpYDKPHVL for STAT1, and FITC-PSpYVNVQN for Grb2. First, 75 nM
of each SH2-containing protein was incubated with the test com-
pound for 15min. Each protein sample was then incubated for
90min with 50 nM of its corresponding FITC-pTyr peptide, and
mixed with streptavidin-coated donor beads and anti-FITC
acceptor beads simultaneously before detection at 570 nm using
EnVisonXcite (Perkin Elmer, Waltham, MA).
Cell culture
The colorectal cancer HCT116 cells were cultured in McCoy’s
media supplemented with penicillin (10,000U/ml), streptomycin
(10mg/ml), nonessential amino acid, and 10% fetal calf serum
(FCS). Cells were then seeded in 48 well plates and, after 24 h,
they were incubated with different concentration of newly synthe-
sized compounds dissolved in DMSO. The same volume of solvent
was added to control conditions and did not exceed 0.5% (v/v).
MTT assay
After 48 h of treatment, medium was removed from each well,
and cells were incubated with fresh medium, containing 10% (v/v)
of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide) reagent. MTT, by interacting with vital cells mitochon-
dria, is converted to formazan, with the development of visible
purple crystals. After dissolving these crystals with isopropanol-
HCl, the quantification of the conversion of MTT to formazan is




Compounds 1, 2, and 5 were prepared through coupling reactions
between valproic acid and S-(2-hydroxyethyl) methanesulfono-
thioate (9) or S-(2-aminoethyl) methanesulfonothioate (10) or
between diclofenac and 9, respectively as previously
described17,24. A similar synthetic route was used for the synthesis
of 326 and 427 as indicated in Scheme 1.
Compound 6 was obtained by reacting sodium toluenethiosul-
fonate (12), prepared accordingly to29, with 4-(2-chloroacetamido)-
2-hydroxybenzoic acid (11; Scheme 2). This latter was prepared
from the reaction of p-aminosalicylic acid with chloroacetyl chlor-
ide as described by Harte and Gunnlaugsson30.
Since the analogous reaction of sodium methanethiosulfonate
(13) with 4-(2-chloroacetamido)-2-hydroxybenzoic acid (11) did
not afford the desired 2-hydroxy-4-(2-((methylsulfonyl)thio)aceta-
mido)benzoic acid (7), we tried to obtain it through a coupling
reaction between p-aminosalicylic acid (PAS) and 2-((methylsulfo-
nyl)thio)acetic acid (15). This latter was prepared by reacting com-
pound 13 with bromoacetic acid (14), following with few
modifications the methods previously described36,37 (Scheme 3).
Surprisingly, instead of the methanethiosulfonate derivative (7),
S-((methylsulfonyl)methyl) 4-amino-2-hydroxybenzothioate (8) was
obtained in low yield through an, at the present, undefined mech-
anism possibly involving a concerted decarboxylation and
rearrangement of the methanesulfonylthioacetic acid (15).
In order to unambiguously assess the molecular structure, we
performed on compound 8 the crystallographic analysis and the
Scheme 1. Reagents and conditions: (a) DCC, DMAP, CH2Cl2, rt, 1.5 h.
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ORTEP34 drawing is shown in Figure 3. In the molecule, the central
-S–C¼O moiety is approximately coplanar with respect to the
p-aminosalicylic system, which presents a strong intramolecular
O-H…O hydrogen bond. The conformation of the lateral chain is
characterized by a torsion angle C7-S2-C8-S1 of 36(1). In the crys-
tal, molecules are linked by N-H…O hydrogen-bonding interac-
tions, forming chains parallel to the b-axis direction.
Biological results
The thiosulfonate-drug hybrids 1–5, the S3I-201 analog 6 and
compound 8, together with their parent compounds have been
submitted to the AlphaScreen-based assay, to investigate their
ability to directly bind STAT3-SH2 domain.
Moreover, in order to check the selectivity of our molecules on
STAT3, other SH2-containing proteins, such as STAT1 and Gbr2
(Growth factor receptor-bound protein 2), highly homolog to
STAT3 (78% and 65%, respectively), have also been tested. Results,
expressed as % of protein inhibition at 30 and 3 lM concentration
or as IC50 (lM), are reported in Table 1. In addition, the
cytotoxicity35 of these compounds on HCT-116 cell line (a human
colon carcinoma cell line which expresses high levels of STAT338)
was also tested. The inhibitory activities (IC50 lM values) are also
listed in Table 1.
The obtained results indicate that all thiosulfonate hybrids are
able to strongly and selectively bind STAT3-SH2 domain, whereas
the parent drugs were completely devoid of this activity at the
highest concentration tested (30lM). Although NSAIDs such as
acetylsalicylic acid and sulindac are reported to induce STAT3
downregulation22,23, these results indicate that these drugs are
not able to directly bind to the SH2 domain of the protein. Even
the thiosulfonic parent compounds 9 and 1017 lower inhibited
STAT3 compared to their corresponding drug hybrids, possibly for
their higher hydrophilicity or too small size. Indeed, small metha-
nethiosulfonate derivatives have been previously used to examine
the accessibility of cysteine residues in ion channel and receptor
proteins39–42, because these reagents can react with the free thiol
group of cysteine residues to form a mixed disulfide between the
cysteine sulfur and the electrophilic moiety of the reagent. Of
course, if the cysteine residue is in a critical region, the additional
Scheme 2. Reagents and conditions: (a) anh. DMF, N2, 60 C, 4 h.
Scheme 3. Reagents and conditions: (a) acetone, rt, 20 h; 80%. (b) HOBt, EDC-HCl, DIPEA, anh. DMF, Ar, 0 C to rt, 5 h; 6%.
Figure 3. Left: ORTEP34 drawing of 8, showing the arbitrary atomic numbering (displacement ellipsoids at 40% probability). Right: Intermolecular interactions viewed
about along a-axis.
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mass prevents normal function of the protein. In our case, the dif-
ferent inhibitory activity of our compounds suggests that bulky
and lipophilic molecules are required. However, docking studies
should be performed on these methanthiosulfonate hybrids in
order to deeply investigate their interaction with STAT3-SH2
domain.
Despite the excellent in vitro STAT3 inhibition of the thiosulfo-
nate-drug hybrids, only three compounds, 1, 3, and 4 showed a
moderate antiproliferative activity on HCT-116 cell line, whereas the
other two potent compounds, 2 and 5, were inefficacious at con-
centration up to 100–200 lM. Since the STAT3 inhibition has been
tested in a cell-free assay, the low cytotoxicity of the tested com-
pounds could be related to their physicochemical properties, such
as poor solubility and chemical stability in the culture medium
(time-related hydrolysis), cell permeation, and enzymatic hydrolysis
inside cells. These latter should be deeply explored in further stud-
ies, together with the cytotoxicity against other cancer cell lines.
As far as the new S3I-201 analog 6, the AlphaScreen results
showed that it better interacts with the STAT3-SH2 domain com-
pared to the parent compound (58.4% versus 7.2% of inhibition at
30lM). Once again, this finding indicates the ability of the thiosul-
fonate moiety to bind the STAT3 SH2-domain. However, com-
pound 6 did not exhibit any cytotoxic effect up to 200lM,
suggesting that it does not reach the target in whole cells, maybe
for its low stability or for permeability reasons, which should be
better explored.
Interestingly, compound 8, characterized by an unusual sulfur-
ated functionality, moderately inhibited STAT3-SH2 domain at
30lM and exhibited a good cytotoxic activity on HCT-116 cell line
which is comparable to that of S3I-201 and is worthy of further
investigation.
Conclusions
A set of thiosulfonic derivatives has been synthesized and tested
in vitro by means of an AlphaScreen-based assay to investigate their
ability to interact with STAT3-SH2 domain. Among the tested com-
pounds, all the methanthiosulfonate drug hybrids were able to
strongly and selectively bind STAT3-SH2 domain, with IC50 in low
micromolar or submicromolar range, whereas the parent drugs
were completely devoid of this ability. However, only few com-
pounds showed a moderate cytotoxic activity on HCT-116 cell line,
suggesting that, probably, these compounds do not reach easily
their intracellular target due to unsuitable physicochemical proper-
ties. Therefore, further studies on chemical stability in the culture
medium, as well as on solubility and cell permeability, are needed.
The obtained results suggest that the methanethiosulfonate
moiety represents a useful scaffold for the synthesis of new direct
STAT3 inhibitors and the methanethiosulfonate drug hybrids
described in this manuscript can be considered interesting hit
compounds worthy of structural optimization.
Worth of note is the occasional isolation of a compound with
an unusual sulfurated functionality (8) and endowed with valuable
antiproliferative activity on HCT-116 cell line, deserving further
investigation.
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